Zacks Research Analysts Increase Earnings Estimates for MMSI

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Equities research analysts at Zacks Research lifted their Q4 2025 earnings per share estimates for Merit Medical Systems in a research note issued on Wednesday, August 20th. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings of $0.82 per share for the quarter, up from their prior forecast of $0.75. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.37 per share. Zacks Research also issued estimates for Merit Medical Systems’ Q1 2026 earnings at $0.77 EPS, Q3 2026 earnings at $0.88 EPS, Q4 2026 earnings at $0.96 EPS and Q1 2027 earnings at $0.84 EPS.

Other research analysts have also recently issued reports about the stock. Piper Sandler reduced their target price on shares of Merit Medical Systems from $110.00 to $105.00 and set an “overweight” rating on the stock in a research report on Thursday, July 31st. Canaccord Genuity Group set a $112.00 price target on shares of Merit Medical Systems and gave the stock a “buy” rating in a research note on Wednesday, May 21st. Raymond James Financial decreased their price objective on shares of Merit Medical Systems from $108.00 to $102.00 and set an “outperform” rating for the company in a research report on Thursday, July 31st. Barrington Research restated an “outperform” rating and set a $103.00 target price on shares of Merit Medical Systems in a research note on Thursday, July 31st. Finally, Wells Fargo & Company cut their price target on Merit Medical Systems from $108.00 to $100.00 and set an “overweight” rating on the stock in a research note on Thursday, July 31st. Eight research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $107.00.

Merit Medical Systems Stock Up 1.0%

NASDAQ MMSI opened at $89.06 on Monday. The company has a quick ratio of 2.66, a current ratio of 4.09 and a debt-to-equity ratio of 0.49. Merit Medical Systems has a fifty-two week low of $81.04 and a fifty-two week high of $111.45. The business has a 50 day moving average price of $88.54 and a two-hundred day moving average price of $94.75. The stock has a market cap of $5.27 billion, a PE ratio of 45.21, a P/E/G ratio of 2.86 and a beta of 0.66.

Merit Medical Systems (NASDAQ:MMSI) last posted its earnings results on Wednesday, July 30th. The medical instruments supplier reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.16. The business had revenue of $382.46 million during the quarter, compared to analyst estimates of $372.47 million. Merit Medical Systems had a return on equity of 15.07% and a net margin of 8.31%.The company’s revenue for the quarter was up 13.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.92 earnings per share.

Insiders Place Their Bets

In related news, Director Lynne N. Ward sold 3,000 shares of the business’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $88.56, for a total value of $265,680.00. Following the completion of the sale, the director directly owned 12,809 shares of the company’s stock, valued at $1,134,365.04. The trade was a 18.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Raul Jr. Parra sold 15,181 shares of the company’s stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $93.75, for a total value of $1,423,218.75. Following the sale, the chief financial officer owned 24,201 shares in the company, valued at $2,268,843.75. The trade was a 38.55% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 49,779 shares of company stock valued at $4,662,863. 3.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Merit Medical Systems

Hedge funds have recently added to or reduced their stakes in the business. Maseco LLP acquired a new stake in shares of Merit Medical Systems during the second quarter worth $28,000. Opal Wealth Advisors LLC bought a new stake in shares of Merit Medical Systems during the 1st quarter valued at about $31,000. IFP Advisors Inc grew its position in shares of Merit Medical Systems by 1,435.0% during the 1st quarter. IFP Advisors Inc now owns 307 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 287 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in Merit Medical Systems by 55.6% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 375 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 134 shares during the period. Finally, Northwestern Mutual Wealth Management Co. raised its stake in Merit Medical Systems by 119.8% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 367 shares of the medical instruments supplier’s stock worth $39,000 after acquiring an additional 200 shares during the period. Institutional investors and hedge funds own 99.66% of the company’s stock.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.